Skip to content

Study · Randomized controlled trial · n = 67 · 2021

6 results

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.

Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L

Alimentary pharmacology & therapeutics27 Sept 2021Cited by 189 (Europe PMC)

PMID34570916 (opens in a new tab)PMCIDPMC9292692 (opens in a new tab)DOI10.1111/apt.16608 (opens in a new tab)PepBankPUB-34570916
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In subjects with NAFLD, semaglutide did not change liver stiffness by MRE significantly differently from placebo at week 48 or at weeks 24 and 72.

    In plain wordsIn people with fatty liver disease, semaglutide did not change liver stiffness differently from placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeLiver stiffness by MRE, change from baseline to week 48
    Study

    n = 67

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.4 mg once daily · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Estimated treatment ratio
    0.96 ratio
    week 48 versus placebo

    Source sentences

    Summary
    Change from baseline in liver stiffness was not significantly different between semaglutide and placebo at week 48 (estimated treatment ratio 0.96 (95% CI 0.89, 1.03; P = 0.2798); significant differences in liver stiffness were not observed at weeks 24 or 72.
    2 context sentences
    Summary · context
    This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF).
    Summary · context
    Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In subjects with NAFLD, semaglutide reduced liver steatosis by MRI-PDFF significantly more than placebo at weeks 24, 48 and 72.

    In plain wordsIn people with fatty liver disease, semaglutide reduced liver fat more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver steatosis by MRI-PDFF
    Study

    n = 67

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.4 mg once daily · subcutaneousAs given in this study (human).

    Measurements

    Estimated treatment ratio
    0.7 ratio
    week 24
    Estimated treatment ratio
    0.47 ratio
    week 48
    Estimated treatment ratio
    0.5 ratio
    week 72

    Source sentences

    Summary
    Reductions in liver steatosis were significantly greater with semaglutide (estimated treatment ratios: 0.70 [0.59, 0.84], P = 0.0002; 0.47 [0.36, 0.60], P < 0.0001; and 0.50 [0.39, 0.66], P < 0.0001)
    2 context sentences
    Summary · context
    This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF).
    Summary · context
    Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In subjects with NAFLD, more subjects achieved a reduction in liver fat content of at least 30% with semaglutide than with placebo at weeks 24, 48 and 72.

    In plain wordsIn people with fatty liver disease, more people on semaglutide than on placebo lost at least 30% of liver fat.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with at least 30% reduction in liver fat content
    Study

    n = 67

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.4 mg once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    more subjects achieved a ≥ 30% reduction in liver fat content with semaglutide at weeks 24, 48 and 72, (all P < 0.001).
    2 context sentences
    Summary · context
    This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF).
    Summary · context
    Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In subjects with NAFLD, liver enzymes decreased with semaglutide.

    In plain wordsIn people with fatty liver disease, liver enzymes went down with semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver enzymes
    Study

    n = 67

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.4 mg once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Decreases in liver enzymes, body weight and HbA1c were also observed with semaglutide.
    2 context sentences
    Summary · context
    This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF).
    Summary · context
    Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In subjects with NAFLD, body weight decreased with semaglutide.

    In plain wordsIn people with fatty liver disease, body weight went down with semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 67

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.4 mg once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Decreases in liver enzymes, body weight and HbA1c were also observed with semaglutide.
    2 context sentences
    Summary · context
    This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF).
    Summary · context
    Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In subjects with NAFLD, HbA1c decreased with semaglutide.

    In plain wordsIn people with fatty liver disease, HbA1c went down with semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 67

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Decreases in liver enzymes, body weight and HbA1c were also observed with semaglutide.
    2 context sentences
    Summary · context
    This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF).
    Summary · context
    Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT03357380

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

Novo Nordisk A/Sn = 6728 Nov 2017 to 20 Mar 2020

Hepatobiliary Disorders · Non-alcoholic Fatty Liver Disease

Trial pageClinicalTrials.govUpdated 22 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.